The morning pre-op review is already overloaded
Pre-operative review is now a compression exercise rather than a contemplative consult. Anesthesia teams are expected to scan problem lists, medication history, prior anesthetic reactions, cardiopulmonary clues, current labs, and the procedural plan in minutes, often while the first rooms are already turning over. That workflow rewards signal density. Anything new must justify itself by helping the team see risk earlier or act with more confidence.
That is exactly why CYP450 data belongs in the conversation. Pharmacogenomics has often been treated like an optional research layer that lives somewhere outside real surgical operations. In practice, the medications shaped by CYP metabolism already sit in the middle of perioperative work. Opioids, antiemetics, antidepressants, beta blockers, and supportive medications all move through the pre-op, intraoperative, and recovery-room pathway. The question is no longer whether genetics matters. The question is whether teams can afford to ignore it when the evidence is already present.
Drug-gene signal changes perioperative assumptions
A CYP2D6 poor metabolizer may not activate codeine or tramadol as expected, which means a standard post-op analgesic pathway can quietly underperform. An ultrarapid metabolizer can push in the opposite direction and produce a stronger response than clinicians intended. CYP2C19 and CYP3A5 variation can alter how supportive medications behave around surgery as well. None of this replaces clinical judgment, but it absolutely changes the baseline assumption that a standard medication plan will behave the same way for every patient.
Perioperative risk is almost never about one drug in a vacuum. It is about the interaction stack: genotype, comorbid disease, obesity, organ function, sleep apnea, age, baseline medication burden, and the rescue therapies that appear when the first plan does not work. That is why pharmacogenomics matters most in surgery. The perioperative window compresses physiologic stress, multiple medication classes, and tight monitoring expectations into a very small amount of time.
- Variant-driven under-response can lead to repeat dosing, rescue escalation, and delayed comfort control.
- Variant-driven over-response can increase respiratory compromise, oversedation, and recovery-room instability.
- Medication-genomic interactions become more dangerous when layered onto frailty, organ dysfunction, or dense pain regimens.
The team needs a planning cue, not a genetics lecture
Anesthesia teams do not need a genomic monograph in the middle of a morning case stack. They need a short operational translation. If a known genotype suggests a standard medication may underperform or overperform, the workflow should surface that fact in the same place the team already reviews the rest of the case. The value is not in exposing raw lab language. The value is in reducing ambiguity at the moment planning choices are still easy to change.
That means the checklist item is not simply genomics available. It is a risk-translation layer. The interface should tell the team that a relevant variant exists, which perioperative medications are likely to be affected, and whether the result supports alternate analgesia, altered monitoring expectations, or a more deliberate post-op observation plan. When genomics is framed this way, it stops feeling like a separate specialty program and starts behaving like another legitimate dimension of perioperative preparation.
- Known pharmacogenomic variant and the phenotype that matters clinically
- Medication classes likely to be affected in this perioperative context
- Suggested action: alternate agent, altered expectation, or closer follow-up
Most organizations already have more signal than they think
Hospitals often assume genomic integration means launching a large precision-medicine program before any perioperative use case is possible. In reality, many organizations already have fragments of the necessary data. A discrete result may already be in the EHR. A genetics lab relationship may already exist. Some systems have ambulatory pharmacogenomic testing workflows that never make it into the OR conversation. The limiting factor is usually not total absence of data. It is the failure to surface that data in the perioperative moment.
This is where a broader perioperative risk platform becomes useful. Genomics should not arrive as an isolated tab that forces the clinician to translate everything manually. It should sit alongside other drivers such as cardiopulmonary burden, renal function, bleeding risk, prior complications, and procedural context. The team still has one risk conversation, but it becomes more precise because medication sensitivity is now part of the reasoning instead of an invisible variable.
A practical adoption path starts smaller than people expect
The smartest starting point is not every service line, every drug, and every patient. It is the part of the workflow where medication uncertainty already causes predictable operational pain. Opioid response is one obvious entry point. Antiemetic planning and patients with especially dense medication histories are others. When the use case is concrete, teams can evaluate whether genomics is changing discussion quality, post-op expectations, and medication selection in a way clinicians actually trust.
From there, departments can expand into service lines where the operational payoff is easier to observe. High-volume orthopedics, ambulatory programs, or complex general surgery may each provide a different kind of proof. The goal is not to make pre-op noisier. The goal is to remove uncertainty where the medication plan is already fragile and where a small planning change can prevent a larger downstream problem.
Governance is what turns signal into a durable workflow
Any department adopting perioperative genomics should ask the same practical questions it would ask of any other risk input. Where did the result come from. How current is it. How is it surfaced. Which medications and decisions does it affect. Who validates the interpretation logic. Those governance questions are not bureaucracy. They are what make clinicians comfortable trusting the signal without treating it as background decoration.
That is the real case for making CYP450 variants part of the pre-op checklist. The issue is not novelty. It is risk visibility. If genotype can change how a standard medication behaves, and if medication behavior can change recovery quality, respiratory stability, or escalation patterns, then leaving that signal out of perioperative review is no longer neutral. It is simply a missed opportunity to make a high-pressure workflow a little more precise.
